$NGENF Dr. Mikol is giving his presentation today on our NVG-291 1b/2a Alzheimers trial design at the Alzheimer's Association International Confrence. August 3, 2022. NervGen's Chief Medical Officer, Dr. Daniel Mikol, will present a poster summarizing unblinded data from the single ascending dose (SAD) cohort of the study and interim blinded data from the multiple ascending dose (MAD) portion of the study, and for the first time will introduce the study design for the upcoming Phase 1b/2a trial of NervGen's lead drug candidate, NVG-291, in subjects with mild cognitive impairment or mild dementia due to Alzheimer's disease. Great conference to further get our name and drug out into the scientific community.